文献速递前列腺增生与排尿功能障碍

一种用于扩展和重塑前列腺尿道以治疗良性前列腺增生的新型植入物的表征:犬模型临床前可行性研究

Characterization of a Novel Implant Intended to Expand and Reshape the Prostatic Urethra for the Treatment of Benign Prostatic Hyperplasia: A Pre-Clinical Feasibility Study in the Canine Model.
PubMed 文献 · Urology · 2021-10-30

在8只成年雄性犬中评估第一代Urocross扩展器系统(Mercury扩展器系统)的安全性和可行性,植入物经柔性膀胱镜置入并取出,按取出时间分为1、6、12个月三组。结果显示尿道宽度从6.9±1.8 mm增至10.2±0.6 mm(P=.012)并在留置期间保持,所有受试犬保持控尿且无梗阻或尿潴留,植入物无结壳、组织生长或结石形成。

要点

  • 尿道宽度从6.9±1.8 mm增至10.2±0.6 mm(P=.012),并在留置期间保持。
  • 所有8只犬保持控尿,无梗阻或尿潴留。
  • 植入物取出后表面无组织生长、结壳或结石形成。

核心结论

  • 第一代Urocross扩展器系统在犬模型中显示出良好的安全性特征。
  • 前列腺尿道形状发生改变,留置期间尿道宽度增加,组织变化轻微。
  • 植入物未显示任何结壳、组织生长或结石形成。

研究设计与样本

  • 在8只成年雄性犬中部署和取出植入物,使用柔性膀胱镜操作。
  • 按取出日期分为1个月、6个月和12个月三个研究组。
  • 通过膀胱镜和尿道造影验证植入物位置/直径、膀胱颈和外括约肌功能/变化、前列腺组织反应及植入物状况。
  • 取出后1个月,对前列腺及周围组织切片并由兽医病理学家评估。

主要发现

  • 所有植入物成功部署于前列腺尿道。
  • 尿道宽度从6.9±1.8 mm增至10.2±0.6 mm(P=.012),并在留置期间保持。
  • 尿道长度和外括约肌直径无显著变化。
  • 所有受试犬(n=8)保持控尿,无梗阻或尿潴留。
  • 不良事件包括切口部位出血(n=2)和短暂血尿(n=3);一枚植入物迁移至膀胱并自行复位至前列腺尿道。

关键数值与推荐

  • 取出后植入物表面无组织生长、结壳或结石形成。
  • 影像学显示接触部位红斑和压痕,但无结石、狭窄、穿孔、糜烂或溃疡。
  • 组织病理学显示腺泡改变、炎症和纤维化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety, feasibility, and tissue response of a novel device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia, using the first-generation Urocross Expander System (Mercury Expander System). METHODS: The implant was deployed and retrieved using flexible cystoscope in 8 adult male canines, separated into three study arms by retrieval date (1-, 6-, and 12- months post-deployment). Cystoscopy and urethrograms verified implant position/diameter; bladder neck and external sphincter function/changes; prostatic tissue response; and implant condition. One-month post-retrieval, the prostate and surrounding tissue was sectioned and evaluated by a veterinary pathologist. RESULTS: All implants were successfully deployed in the prostatic urethra. Urethral width was increased (6.9 ± 1.8 mm to 10.2 ± 0.6 mm, P = .012) and preserved through the dwell period. Urethral length and sphincter diameters didn't significantly change. All subjects (n = 8) remained continent without obstruction or retention. Adverse events included incisional site bleeding (n = 2) and transient hematuria (n = 3). One implant migrated into the bladder and spontaneously repositioned into the prostatic urethra. Post-retrieval, explant surfaces demonstrated no tissue growth, encrustation or stone formation. Imaging revealed contact site erythema and indentation, but no stones, strictures, perforations, erosions, nor ulcerations. Histopathology revealed glandular acinar changes, inflammation, and fibrosis. CONCLUSION: The first generation of the Urocross Expander System demonstrated a favorable safety profile in the canine model. Changes in the prostatic urethra shape were noted with an increase in urethral width during the dwell period with minimal tissue changes. Further, the implant didn't demonstrate any encrustation, tissue growth or stone formation.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Chughtai B, Punyala A, Lata SS, et al. Characterization of a Novel Implant Intended to Expand and Reshape the Prostatic Urethra for the Treatment of Benign Prostatic Hyperplasia: A Pre-Clinical Feasibility Study in the Canine Model. Urology. 2021. PMID: 34728332. doi:10.1016/j.urology.2021.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。